MedTrace Logo

Single Dose of 9-cis-retinoic Acid in Hepatic Patients

NCT01891526 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2013-07-03

No results posted yet for this study

Summary

To test whether patients with hepatic insufficiency can tolerate one oral dose of 9-cis-retinoic acid and to test whether the metabolism of retinoic acid is altered.

Conditions

  • Hepatic Insufficiency

Interventions

DRUG

9-cis-retinoic acid

Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure

Sponsors & Collaborators

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01891526 on ClinicalTrials.gov